1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
SMS Lifesciences India Limited

SMS Lifesciences India Limited

SMSLIFE.NS
SMS Lifesciences India LimitedIN flagNational Stock Exchange of India
1,299.00
INR
+10.50
- -
3.93BMarket Cap
SMS Lifesciences India Limited
SMSLIFE.NS
(National Stock Exchange of India)

Recent

price

1,299.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
702.24
690.8
1,234.48
848.83
851.58
1,148.76
1,033.8
990.84
1,113.96
1,080.9
Revenue per Share
-0.01
42.81
21.5
59.03
33.68
44.84
83.76
37.92
30.08
66.51
57.12
Basic EPS, GAAP
- -
40.05
14.89
18.44
-29.13
-1.28
-206.38
-111.98
11.37
61.87
- -
Free Cash Flow per Basic Share
- -
- -
- -
4.69
1.81
- -
- -
1.5
1.5
1.5
- -
Dividend per Share
3.12
45.17
76.86
136.14
167.24
208.53
270.9
305.07
325.58
384.28
- -
Book Value per Share
228.41
270.69
292.35
295.49
326.14
370.87
545.15
622.31
640.32
701.21
- -
Tangible Book Value per Share
3
3
3
3
3
3
3
3
3
3
3
Basic Weighted Avg Shares
- -
2,123
2,088
3,732
2,566
2,575
3,473
3,125
2,996
3,368
3,267
Sales/Revenue/Turnover
- -
10.82
3.63
7.63
6.85
8.69
7.1
5.77
5.44
8.95
7.77
Operating Margin (%)
- -
56
57
64
79
79
100
108
149
150
151
Depreciation Expense
- -
129
65
178
102
136
253
115
91
201
173
Net Income, GAAP
- -
29.89
- -
29.69
30.58
30.72
22.7
31.43
35.74
28.47
29.03
Effective Tax Rate (%)
- -
6.1
3.11
4.78
3.97
5.27
7.29
3.67
3.04
5.97
5.28
Profit Margin (%)
211
259
248
173
202
122
206
256
107
85
- -
Working Capital
233
160
152
272
376
391
422
562
355
200
- -
LT Debt
691
818
884
1,063
1,157
1,292
1,649
1,882
1,936
2,120
- -
Total Equity
- -
15.24
- -
14.91
7.33
8.27
8.69
4.66
3.6
7.36
- -
Return on Invested Capital (%)
- -
43.34
- -
30.06
13.12
13.53
19.71
8.25
8.52
12.69
25.51
Return on Capital (%)
- -
177.31
35.24
55.43
22.2
23.87
34.94
13.17
9.54
18.74
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
664
- -
LT Borrowings
- -
183
- -
LT Finance Leases
- -
17
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
3
- -
Market Capitalization
3,555
3,259
3,675

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
1,506
- -
Cash, Cash Equivalents & STI
- -
15
- -
Accounts Receivable, Net
- -
688
- -
Inventories
- -
674
- -
Total Current Liabilities
- -
1,421
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
664
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.16%
9.51%
Free Cash Flow
- -
3,246.37%
444.14%
Net Income, GAAP
- -
33.13%
121.15%
Sales/Revenue/Turnover
- -
6.7%
12.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
747
693
721
836
2,996
2025
925
785
846
812
3,368
2026
825
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.94
2.24
14.24
- -
30.08
2025
22.99
15.46
18.08
- -
66.51
2026
13.75
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.5
2025
- -
- -
- -
- -
1.5
2026
- -
- -
- -
- -
- -
Similar Companies
NewAmsterdam Pharma Company N.V. (NAMSW)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK)
Bellerophon Therapeutics, Inc. (BLPH)
Inovio Pharmaceuticals, Inc. (GBM.F)
Precision BioSciences, Inc. (DTIL)
Vyant Bio, Inc. (VYNT)
Business
SMS Lifesciences India Limited, formerly known as SMS Lifesciences India Limited and renamed Haleos Labs Limited in August 2025, manufactures active pharmaceutical ingredients, intermediates and provides contract development and manufacturing organization services; its portfolio spans therapeutic segments including anti-ulcer, anti-erectile dysfunction and others such as Famotidine API with 15 tons per month capacity, vertically integrated production and certifications from USFDA, WHO-GMP, COFEPRIS, KFDA and PMDA; the company operates three multi-product facilities and a research center, exports to international markets and serves domestic customers including Cadila Pharmaceuticals and Mylan Laboratories. Founded in 1990 and headquartered in Hyderabad, Telangana, the public-listed firm conducts operations through facilities in Khazipally and Sanath Nagar in Hyderabad with Unit IV expansion for synthetic organic chemicals; it maintains a subsidiary Mahi Drugs Private Limited in Visakhapatnam. Recent developments include robust financial performance with Q2 FY25 profit after tax surging 587% year-over-year to Rs 4.67 crore, sales growth of 26% and declaration of Rs 1.50 per share dividend for FY24 alongside approval for material related party transactions exceeding 10% of consolidated turnover; the company reduced its debt-equity ratio to 0.49 times and pursues ongoing related party engagements with affiliates.